A phase II open label study of cabazitaxel in patients with advanced or metastatic transitional cell carcinoma of the urothelium who have progressed <12 months after a previous platinum based chemotherapy.
Phase of Trial: Phase II
Latest Information Update: 02 Jun 2015
At a glance
- Drugs Cabazitaxel (Primary)
- Indications Urogenital cancer
- Focus Therapeutic Use
- Sponsors Sanofi
- 02 Jun 2015 Results for safety presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
- 02 Jun 2015 Results for efficacy presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
- 02 Jun 2015 Primary endpoint has not been met. (Objective clinical response rate of ≥20%)